Search

Insulin and AHCL were initiated in auto mode (algorithm glucose target 100-120 mg/dl (5.5-6.7 mmol/l), AIT 2-4 h and automated bolus correction ON) and was used continuously for 12 weeks of the study. Keywords: Type 1 diabetes; Continuous subcutaneous insulin infusion; Continuous glucose monitoring; Diabetes education; Closed-loop systems EN Type 1 diabetes Continuous subcutaneous insulin infusion Continuous glucose monitoring Diabetes education Closed-loop systems 743 746 4 04/12/22 20220501 NES 220501 Introduction One of the latest automated insulin Delivery (AID) systems is the advanced hybrid closed-loop (AHCL), the MiniMed 780G system (Medtronic, Northridge, CA, USA), which automatically delivers basal insulin with a customizable glucose target in addition to automated bolus correction, as required. Type 1 diabetes, Continuous glucose monitoring, Diabetes education, Closed-loop systems, Continuous subcutaneous insulin infusion. [Extracted from the article]

Objective: To evaluate the effect of a 1-year hybrid closed-loop (HCL) system on glycemic control in children and adolescents with type 1 diabetes (T1D) previously treated with multiple daily injections (MDI). Methods: This was a 1-year observational study, as a continuation of the previous 3 months prospective study of pediatric patients with T1D conducted at Sidra Medicine in Qatar. The study enrolled individuals aged 7–18 years with T1D > 1 year, on MDI with self-monitoring of blood glucose or continuous glucose monitoring, with no prior pump experience, and with an HbA1c level < 12.5% (< 113 mmol/mol). After the first 3 months of HCL use, patients were followed at 6, 9 and 12 months, where HbA1c was obtained and pump data were collected. Results: All 30 participants (age 10.24 ± 2.6 years) who initiated HCL completed 12 months of HCL system use in Auto Mode. The participants used the sensor 88.4 ± 6.5% of the time with Auto Mode usage 85.6 ± 7.4% during 12 months of HCL system use. HbA1c decreased from 8.2 ± 1.4% (66 ± 15.3 mmol/mol) at baseline, to 6.7 ± 0.5% (50 ± 5.5 mmol/mol) at 3 months (p = 0.02) and remained stable to 7.1 ± 0.6 (54 ± 6.6 mmol/mol) at 12 months (p = 0.02). TIR (70–180 mg/dL) increased from 46.9% at baseline to 71.9% at 1 month and remained above 70% during the 12 months of HCL use. Conclusion: HCL system (MiniMed 670G) in children and adolescents previously treated with MDI significantly improves glycemic outcomes (HbA1c and Time in Ranges) immediately during the first month. This improved glycemic control was maintained over the 1 year following Auto Mode initiation. [ABSTRACT FROM AUTHOR]